The Winners and Losers of the Global Cannabis Industry

Tamir Gedo, CEO, BOL Pharma

- **Investment Rational**

BOLS's main focus and objectives is to create and establish a horizontal platform to reach as many patients, addressing their medical conditions through accurate, consistent, stable Pharma graded products and delivery systems to meet major clinical and vast horizontal solutions for their related health conditions.

- **Business Strategy**

BOL had set itself as a Pharma oriented company, and as such- it had built both its long and short term strategies by setting strategic alliances and positioning itself through strong distribution channels within the Pharma retail and healthcare industries, and within the relevant legalized cannabis markets, globally.

- **Core Technology**

As the company advances and propels the entire medical cannabis industry forward through its advanced research and development processes and key scientific innovations through its highly skilled human resources structure, so does its value and valuation increases, in conjunction to a wide portfolio of clinical trials and medicinal products research and development.

- **Product Profile/Pipeline**

BOL has set itself in a unique position and expansion capabilities and strategies to capture significant market value and positioning within key strategic territories including but not limited to the European continent and North America, without having to rely solely on its Israeli hub, as well as obtaining the ability for prompt supplies based on growing demands.

- **What's Next?**

BOL constantly expands its own capabilities, including expansion of its clinical trials and medical collaboration with hospitals and leading scientists all over the worlds, advancing to medical and scientific breakthroughs. By targeting the global cannabis space BOL is examining its global expansion and growth plans to meet the growing challenges and demands.